When terazosin is combined with a drug that prevents brain cells from converting pyruvate into lactate, energy production improves more than with terazosin alone, leading to even greater reduction in seizures in APOE4 mice, indicating that the pathway of energy use matters for seizure control.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether combining PGK1 activators with LDH inhibitors reduces seizure burden more effectively than either agent alone in human APOE4 carriers with epilepsy.
A systematic review and meta-analysis of all preclinical and clinical studies testing PGK1 activators combined with LDH inhibitors (e.g., oxamate, GSK2837808A) in APOE4 carriers with epilepsy, pooling seizure frequency, ATP biomarkers, and safety outcomes.
Whether adding a lactate dehydrogenase inhibitor to terazosin improves seizure control more than terazosin alone in APOE4 homozygous adults with epilepsy.
A double-blind, four-arm RCT of 160 APOE4/4 adults with focal epilepsy, randomized to terazosin 1 mg/day, sodium oxamate 1 g/day, combination therapy, or placebo for 24 weeks, with primary outcome being reduction in seizure frequency and secondary outcomes including hippocampal ATP via MRS and plasma lactate/pyruvate ratio.
Whether APOE4 carriers with epilepsy who naturally have lower lactate-to-pyruvate ratios in CSF have lower seizure frequency.
A prospective cohort of 200 APOE4 carriers with epilepsy, followed for 3 years with quarterly CSF analysis of lactate, pyruvate, and ATP metabolites, EEG monitoring, and seizure diaries, adjusting for medication and disease stage.
Whether APOE4 carriers with frequent seizures have higher hippocampal lactate-to-pyruvate ratios than those with infrequent seizures.
A case-control study comparing 40 APOE4 carriers with frequent seizures (>1/month) to 40 with infrequent seizures (<1/year), matched for age and Aβ burden, analyzing postmortem hippocampal tissue for lactate, pyruvate, and ATP levels via mass spectrometry.
Whether APOE4 carriers with epilepsy have higher hippocampal lactate-to-pyruvate ratios on MRS than non-carriers with similar seizure burden.
A cross-sectional study of 100 individuals with epilepsy (50 APOE4 carriers, 50 non-carriers) matched for seizure frequency and duration, undergoing 3T MRS to quantify hippocampal lactate, pyruvate, and ATP levels.